Molecular Bases of Drug Resistance in Hepatocellular Carcinoma
The poor outcome of patients with non-surgically removable advanced hepatocellular carcinoma (HCC), the most frequent type of primary liver cancer, is mainly due to the high refractoriness of this aggressive tumor to classical chemotherapy. Novel pharmacological approaches based on the use of inhibi...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/6/1663 |
_version_ | 1797564381556375552 |
---|---|
author | Jose J.G. Marin Rocio I.R. Macias Maria J. Monte Marta R. Romero Maitane Asensio Anabel Sanchez-Martin Candela Cives-Losada Alvaro G. Temprano Ricardo Espinosa-Escudero Maria Reviejo Laura H. Bohorquez Oscar Briz |
author_facet | Jose J.G. Marin Rocio I.R. Macias Maria J. Monte Marta R. Romero Maitane Asensio Anabel Sanchez-Martin Candela Cives-Losada Alvaro G. Temprano Ricardo Espinosa-Escudero Maria Reviejo Laura H. Bohorquez Oscar Briz |
author_sort | Jose J.G. Marin |
collection | DOAJ |
description | The poor outcome of patients with non-surgically removable advanced hepatocellular carcinoma (HCC), the most frequent type of primary liver cancer, is mainly due to the high refractoriness of this aggressive tumor to classical chemotherapy. Novel pharmacological approaches based on the use of inhibitors of tyrosine kinases (TKIs), mainly sorafenib and regorafenib, have provided only a modest prolongation of the overall survival in these HCC patients. The present review is an update of the available information regarding our understanding of the molecular bases of mechanisms of chemoresistance (MOC) with a significant impact on the response of HCC to existing pharmacological tools, which include classical chemotherapeutic agents, TKIs and novel immune-sensitizing strategies. Many of the more than one hundred genes involved in seven MOC have been identified as potential biomarkers to predict the failure of treatment, as well as druggable targets to develop novel strategies aimed at increasing the sensitivity of HCC to pharmacological treatments. |
first_indexed | 2024-03-10T18:57:28Z |
format | Article |
id | doaj.art-9e7818cd50f947b2bf3eda36316f57fd |
institution | Directory Open Access Journal |
issn | 2072-6694 |
language | English |
last_indexed | 2024-03-10T18:57:28Z |
publishDate | 2020-06-01 |
publisher | MDPI AG |
record_format | Article |
series | Cancers |
spelling | doaj.art-9e7818cd50f947b2bf3eda36316f57fd2023-11-20T04:41:50ZengMDPI AGCancers2072-66942020-06-01126166310.3390/cancers12061663Molecular Bases of Drug Resistance in Hepatocellular CarcinomaJose J.G. Marin0Rocio I.R. Macias1Maria J. Monte2Marta R. Romero3Maitane Asensio4Anabel Sanchez-Martin5Candela Cives-Losada6Alvaro G. Temprano7Ricardo Espinosa-Escudero8Maria Reviejo9Laura H. Bohorquez10Oscar Briz11Experimental Hepatology and Drug Targeting (HEVEFARM) Group, University of Salamanca, IBSAL, 37007 Salamanca, SpainExperimental Hepatology and Drug Targeting (HEVEFARM) Group, University of Salamanca, IBSAL, 37007 Salamanca, SpainExperimental Hepatology and Drug Targeting (HEVEFARM) Group, University of Salamanca, IBSAL, 37007 Salamanca, SpainExperimental Hepatology and Drug Targeting (HEVEFARM) Group, University of Salamanca, IBSAL, 37007 Salamanca, SpainExperimental Hepatology and Drug Targeting (HEVEFARM) Group, University of Salamanca, IBSAL, 37007 Salamanca, SpainExperimental Hepatology and Drug Targeting (HEVEFARM) Group, University of Salamanca, IBSAL, 37007 Salamanca, SpainExperimental Hepatology and Drug Targeting (HEVEFARM) Group, University of Salamanca, IBSAL, 37007 Salamanca, SpainExperimental Hepatology and Drug Targeting (HEVEFARM) Group, University of Salamanca, IBSAL, 37007 Salamanca, SpainExperimental Hepatology and Drug Targeting (HEVEFARM) Group, University of Salamanca, IBSAL, 37007 Salamanca, SpainExperimental Hepatology and Drug Targeting (HEVEFARM) Group, University of Salamanca, IBSAL, 37007 Salamanca, SpainExperimental Hepatology and Drug Targeting (HEVEFARM) Group, University of Salamanca, IBSAL, 37007 Salamanca, SpainExperimental Hepatology and Drug Targeting (HEVEFARM) Group, University of Salamanca, IBSAL, 37007 Salamanca, SpainThe poor outcome of patients with non-surgically removable advanced hepatocellular carcinoma (HCC), the most frequent type of primary liver cancer, is mainly due to the high refractoriness of this aggressive tumor to classical chemotherapy. Novel pharmacological approaches based on the use of inhibitors of tyrosine kinases (TKIs), mainly sorafenib and regorafenib, have provided only a modest prolongation of the overall survival in these HCC patients. The present review is an update of the available information regarding our understanding of the molecular bases of mechanisms of chemoresistance (MOC) with a significant impact on the response of HCC to existing pharmacological tools, which include classical chemotherapeutic agents, TKIs and novel immune-sensitizing strategies. Many of the more than one hundred genes involved in seven MOC have been identified as potential biomarkers to predict the failure of treatment, as well as druggable targets to develop novel strategies aimed at increasing the sensitivity of HCC to pharmacological treatments.https://www.mdpi.com/2072-6694/12/6/1663apoptosiscancer stem cellDNA repairepithelial-mesenchymal transitionliver cancermetabolism |
spellingShingle | Jose J.G. Marin Rocio I.R. Macias Maria J. Monte Marta R. Romero Maitane Asensio Anabel Sanchez-Martin Candela Cives-Losada Alvaro G. Temprano Ricardo Espinosa-Escudero Maria Reviejo Laura H. Bohorquez Oscar Briz Molecular Bases of Drug Resistance in Hepatocellular Carcinoma Cancers apoptosis cancer stem cell DNA repair epithelial-mesenchymal transition liver cancer metabolism |
title | Molecular Bases of Drug Resistance in Hepatocellular Carcinoma |
title_full | Molecular Bases of Drug Resistance in Hepatocellular Carcinoma |
title_fullStr | Molecular Bases of Drug Resistance in Hepatocellular Carcinoma |
title_full_unstemmed | Molecular Bases of Drug Resistance in Hepatocellular Carcinoma |
title_short | Molecular Bases of Drug Resistance in Hepatocellular Carcinoma |
title_sort | molecular bases of drug resistance in hepatocellular carcinoma |
topic | apoptosis cancer stem cell DNA repair epithelial-mesenchymal transition liver cancer metabolism |
url | https://www.mdpi.com/2072-6694/12/6/1663 |
work_keys_str_mv | AT josejgmarin molecularbasesofdrugresistanceinhepatocellularcarcinoma AT rocioirmacias molecularbasesofdrugresistanceinhepatocellularcarcinoma AT mariajmonte molecularbasesofdrugresistanceinhepatocellularcarcinoma AT martarromero molecularbasesofdrugresistanceinhepatocellularcarcinoma AT maitaneasensio molecularbasesofdrugresistanceinhepatocellularcarcinoma AT anabelsanchezmartin molecularbasesofdrugresistanceinhepatocellularcarcinoma AT candelaciveslosada molecularbasesofdrugresistanceinhepatocellularcarcinoma AT alvarogtemprano molecularbasesofdrugresistanceinhepatocellularcarcinoma AT ricardoespinosaescudero molecularbasesofdrugresistanceinhepatocellularcarcinoma AT mariareviejo molecularbasesofdrugresistanceinhepatocellularcarcinoma AT laurahbohorquez molecularbasesofdrugresistanceinhepatocellularcarcinoma AT oscarbriz molecularbasesofdrugresistanceinhepatocellularcarcinoma |